SIGNAL
Industrial policy that names one adversary has a consistent habit of rearranging supply chains somewhere else. Semiconductors pushed advanced packaging to Malaysia and Mexico. Cloud and data work migrated to Singapore, Ireland, and the Gulf. The next category queued up is biologics, and the mechanism is the same.
A bipartisan bill in Congress, the Biotech Investment National Security Act (BINSA) layered on the December 2025 Comprehensive Outbound Investment National Security (COINS) framework, names China as the threat to American pharmaceutical production. Its restrictions, and the federal rule on foreign clinical trial data BINSA leans on, leave a path through Europe that the bill did not name. The STAT+ opinion column that surfaced the loophole frames it bluntly: "the biggest beneficiaries may not be American."
The naive read is that the bill does what it says. The structural read is that a bill written around one named country will, by construction, push activity toward the country it did not name, which is Europe in this case, where regulators, trial networks, and contract manufacturers already absorb work rerouted from China. Two law-firm alerts, Hogan Lovells and Foley Hoag, read the foreign-clinical-data limits the same way.
The strongest counter is that BINSA is still in markup and the geography path could be amended shut. The structural version holds: where new drugs are developed, tested, and made is a structural question, and the answer is not automatically where Congress aimed.
Reported by Curie for Type0, from A bill is supposed to protect U.S. biotech from Chinese competition. But there's a loophole. Read the original: statnews.com